Kazia Therapeutics insider holds 13.9% stake

Rhea-AI Filing Summary

Kazia Therapeutics Ltd ownership update: A Schedule 13G/A amendment reports that Jorey Chernett beneficially owned 1,588,129 American Depositary Shares as of the close of business on 02/19/2026, representing 13.90% of the class based on 11,426,899 ADS outstanding as of 03/12/2026.

The filing lists sole voting and dispositive power over those ADS and is signed on 03/31/2026.

Insights

Corporate Governance Specialist

Major passive ownership disclosed; voting and disposition powers are held by the reporting person.

The Schedule 13G/A amendment states 1,588,129 ADS and a 13.90% stake calculated from 11,426,899 ADS outstanding as of 03/12/2026. The filing explicitly lists sole voting and dispositive power.

Such a sizable, disclosed stake may draw attention to governance engagement but the filing does not state any plans or changes in intent.

Equity Ownership Analyst

Stake size is material by percentage but the filing is a routine ownership disclosure.

The report ties the ownership percentage to the issuer's registration statement and anchors the share count to 03/12/2026. The position was measured at the close of business on 02/19/2026.

Cash‑flow or trading intentions are not disclosed; subsequent filings would show any activity.

Key Figures

ADS beneficially owned: 1,588,129 ADS Percent of class: 13.90% ADS outstanding: 11,426,899 ADS +1 more

4 metrics

ADS beneficially owned 1,588,129 ADS Beneficial ownership as of 02/19/2026

Percent of class 13.90% Calculated using 11,426,899 ADS outstanding as of 03/12/2026

ADS outstanding 11,426,899 ADS Outstanding ADS figure cited from issuer's Form F-3 (03/17/2026) as of 03/12/2026

Filing signature date 03/31/2026 Schedule 13G/A signed date

Key Terms

American Depositary Shares, Schedule 13G/A, Beneficially owned

3 terms

American Depositary Shares financial

"The aggregate percentage of American Depositary Shares ("ADS") owned by the Reporting Person"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Schedule 13G/A regulatory

"Item 1. (a) Name of issuer: KAZIA THERAPEUTICS LTD"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned financial

"As of the close of business on February 19, 2026, the Reporting Person beneficially owned 1,588,129 ADS"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

What stake does Jorey Chernett hold in Kazia Therapeutics (KZIA)?

Mr. Chernett beneficially owned 1,588,129 ADS, representing 13.90% of the class. This percentage is calculated using 11,426,899 ADS outstanding as of 03/12/2026, per the filing's stated basis for the calculation.

What dates are relevant to the KZIA Schedule 13G/A filing?

The ownership amount is reported as of the close of business on 02/19/2026. The outstanding ADS figure used for the percentage is dated 03/12/2026, and the Schedule 13G/A amendment is signed on 03/31/2026.

Does the filing state whether Chernett can vote or sell the reported ADS?

Yes. The filing indicates the Reporting Person has sole voting power and sole dispositive power over the 1,588,129 ADS, as referenced on the cover page items noted in the Schedule 13G/A.

How was the 13.90% ownership percentage calculated in the KZIA filing?

The percentage is computed using 11,426,899 ADS outstanding as of 03/12/2026, based on the issuer's Form F-3 registration statement filed on 03/17/2026, as cited in the Schedule 13G/A amendment.

Does the Schedule 13G/A disclose any intent to buy or sell more KZIA shares?

No. The amendment reports beneficial ownership and voting/dispositive power but does not state any intent to acquire or dispose of additional ADS or outline trading plans or strategies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/31/2026 - 02:36 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

KAZIA THERAPEUTICS LTD

(Name of Issuer)

American Depositary Shares

(Title of Class of Securities)

48669G105

(CUSIP Number)

03/24/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 48669G105

1

Names of Reporting Persons

Chernett Jorey

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,588,129.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,588,129.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,588,129.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

13.90 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: KAZIA THERAPEUTICS LTD
(b)	Address of issuer's principal executive offices: Three International Towers, Level 24, 300 Barangaroo Avenue, SYDNEY NSW, AUSTRALIA, 2000
Item 2.
(a)	Name of person filing: Jorey Chernett (the "Reporting Person")
(b)	Address or principal business office or, if none, residence: The principal business address of the Reporting Person is 6222 Indianwood Trail, Bloomfield Hills, MI 48301.
(c)	Citizenship: US.
(d)	Title of class of securities: American Depositary Shares
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The aggregate percentage of American Depositary Shares ("ADS") owned by the Reporting Person is calculated based upon 11,426,899 American Depository Shares outstanding as of March 12, 2026 (assuming all outstanding Ordinary Shares were represented by American Depository Shares), as disclosed in the Issuer's Registration Statement on Form F-3, filed with the U.S. Securities and Exchange Commission (the "SEC") on March 17, 2026. As of the close of business on February 19, 2026, the Reporting Person beneficially owned 1,588,129 ADS.
(b)	Percent of class: 13.90%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Cover Pages Items 5-9.
	(ii) Shared power to vote or to direct the vote: See Cover Pages Items 5-9.
	(iii) Sole power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
	(iv) Shared power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Chernett Jorey

Signature:	/s/ Jorey Chernett
Name/Title:	Jorey Chernett
Date:	03/31/2026